Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232

[1]  I. Aldoss,et al.  Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse‐free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia , 2019, Cancer medicine.

[2]  C. Bloomfield,et al.  A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.

[3]  A. Bleyer,et al.  Treatment of young adults with Philadelphia‐negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper‐CVAD vs. pediatric‐inspired regimens , 2018, American journal of hematology.

[4]  M. Loh,et al.  Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. , 2018, Blood.

[5]  A. Baruchel,et al.  Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? , 2018, Blood.

[6]  A. Bleyer,et al.  Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Review , 2018, JAMA oncology.

[7]  T. Klausen,et al.  Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia , 2018, Leukemia.

[8]  M. Loh,et al.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. , 2017, Blood.

[9]  C. Bloomfield,et al.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Loh,et al.  Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Downing,et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[13]  S. Gupta,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 2014, Kathmandu University medical journal.

[14]  B. Leber,et al.  Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia , 2014, Leukemia.

[15]  N. Heerema,et al.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.

[16]  M. Loh,et al.  Acute Lymphoblastic Leukemia , 2006 .

[17]  Xiaomin Lu,et al.  Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Heerema,et al.  Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Brenner,et al.  Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. , 2009, Blood.

[21]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[22]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[23]  C. Bloomfield,et al.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. , 2008, Blood.

[24]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[25]  A. Bleyer,et al.  Delays in cancer diagnosis in underinsured young adults and older adolescents. , 2007, The oncologist.

[26]  S. Richards,et al.  Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials , 2007, Pediatric blood & cancer.

[27]  G. Gustafsson,et al.  Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden , 2006, Cancer.

[28]  P. Sonneveld,et al.  [Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols]. , 2005, Nederlands tijdschrift voor geneeskunde.

[29]  J. Cayuela,et al.  Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[31]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  S. Gomez,et al.  Adoption of pediatric‐inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population‐based study , 2017, Cancer.

[34]  M. Devidas,et al.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children ’ s Oncology Group Study AALL 0031 , 2015 .

[35]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group , 2008 .

[36]  C. Schoen,et al.  Rite of passage? Why young adults become uninsured and how new policies can help. , 2004, Issue brief.

[37]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[38]  K. Schmiegelow,et al.  Results of NOPHO ALL 2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia , 2022 .